BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...cancer, in this case by activating the stimulatory checkpoints rather than blocking the inhibitory ones. GITR...
...interest from two products in 2015 to nine in 2019. The most advanced programs are anti-GITR...
...adhesion molecule 1 CTLA-4 (CTLA4, CD152) - Cytotoxic T-lymphocyte associated protein 4 GITR (TNFRSF18) - Glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein...
BioCentury | Sep 20, 2019
Company News

Sept. 20 Company Quick Takes: Three Japanese approvals, plus AZ-Ironwood, Boehringer-Inflammasome, China Biologics and a Sino-Russian JV

...permanent and exclusive R&D, production and commercialization rights for undisclosed antibodies against IL-17, PD-1 and GITR...
...and autoimmune diseases in China, including mainland China, Hong Kong, Macau and Taiwan. Targets: GITR (TNFRSF18...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...and 4 SD (29%) 2511 Merck & Co. Inc. (NYSE:MRK) MK-4166 Antibody against glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR; TNFRSF18...
BioCentury | Feb 20, 2019
Distillery Therapeutics

Endocrine/metabolic

...INDICATION: Diabetes Mouse studies suggest agonizing GITR could help treat insulin resistance. In genetic and high-fat...
...testing additional GITR agonists in the models. Agenus Inc. and Incyte Corp. have INCAGN1876, a GITR...
...in preclinical testing to treat solid tumors. TARGET/MARKER/PATHWAY: Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR; TNFRSF18...
BioCentury | Dec 21, 2018
Company News

Astellas exercises option to acquire Potenza

...antibody. Potenza Therapeutics Inc., Cambridge, Mass. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer Shannon Lehnbeuter ASP8374, PTZ-201 GITR...
BioCentury | Mar 23, 2018
Emerging Company Profile

Double threat

...depleting Tregs by targeting TNF receptor superfamily member 4 (OX40; TNFRSF4; CD134) or glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR; TNFRSF18...
...lung cancer (NSCLC) and melanoma tumor microenvironments express higher levels of TNFR2 than OX40 or GITR...
...Science Signaling (2017) Elizabeth S. Eaton, Staff Writer Boston Immune Technologies & Therapeutics Inc. Tumor necrosis factor receptor 2 Glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) (TNFRSF18) Tumor...
BioCentury | Oct 27, 2017
Company News

Incyte gains rights to Macrogenics' PD-1 inhibitor

...combine MGA012 with arginase and bromodomain inhibitors, as well as an agonist of glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR; TNFRSF18...
...MacroGenics Inc. (NASDAQ:MGNX), Rockville, Md. Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Business: Cancer Jennie Walters flotetuzumab MGA012 MGD006 MGD007 MGD009 Incyte Corp. MacroGenics Inc. B7-H3 (CD276) CD123 CD3 Glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) (TNFRSF18) Glycoprotein...
BioCentury | Oct 25, 2017
Company News

Incyte gains rights to MacroGenics' PD-1 inhibitor

...combine MGA012 with arginase and bromodomain inhibitors, as well as an agonist of glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR; TNFRSF18...
...$0.51 to $114.55 on Wednesday. Jennie Walters B7-H3 x CD3 DART molecule CD3xCD123 DART molecule epacadostat flotetuzumab gpA33 x CD3 DART molecule MGA012 MGD007 MGD009 GITR Incyte...
BioCentury | Sep 15, 2017
Company News

Five Prime ends antibody deal with Inhibrx

...deal with Inhibrx LLC (La Jolla, Calif.) to develop and commercialize Inhibrx’s preclinical glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR; TNFRSF18...
...told BioCentury the termination was due to pipeline prioritization and the "crowded, competitive landscape" around GITR...
...to GITR and other targets, including lead candidate INBRX-110 , a mAb designed to activate GITR...
BioCentury | Aug 24, 2017
Product R&D

MedImmune's neo stimulus package

...and there are preclinical studies showing this.” David Berman, MedImmune   Berman also noted stimulating GITR...
...could heighten the potency of neoantigen vaccines. The company has MEDI1873 , a fusion protein GITR...
...Louis, St. Louis, Mo. Targets CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4 GITR (TNFRSF18...
Items per page:
1 - 10 of 45